Ebrotidine

Ebrotidine

Ebrotidine is a drug that belongs to the class of H2 receptor antagonists, which are commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by the Spanish pharmaceutical company Esteve.

Pharmacology

Ebrotidine works by blocking histamine receptors in the stomach, specifically H2 receptors. This reduces the production of stomach acid, which can help to alleviate symptoms of conditions such as peptic ulcer disease and gastroesophageal reflux disease. Unlike other H2 receptor antagonists, ebrotidine also has cytoprotective properties, meaning it can help to protect the stomach lining from damage.

Clinical Use

Ebrotidine has been used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It has also been investigated for potential use in the treatment of Helicobacter pylori infections, as it has been shown to have antibacterial activity against this bacterium in vitro.

Side Effects

As with all medications, ebrotidine can cause side effects. These may include headache, dizziness, and gastrointestinal symptoms such as nausea and diarrhea. In rare cases, it can cause more serious side effects such as liver damage.

History

Ebrotidine was developed by the Spanish pharmaceutical company Esteve in the 1980s. It was first approved for use in Spain in 1993, and has since been approved in several other countries.

See Also

• H2 receptor antagonist
• Peptic ulcer disease
• Gastroesophageal reflux disease
• Helicobacter pylori

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology

This article is a stub related to pharmacology. You can help WikiMD by expanding it!